Off-label information dissemination for serious illnesses will be studied by AMA board.
OFF-LABEL USE INFORMATION DISSEMINATION FOR CATASTROPHIC ILLNESS will be studied by the American Medical Association under a resolution adopted by the AMA House of Delegates June 25 at its annual meeting in Chicago. The policy directs the AMA Board of Trustees to prepare "an in-depth study of the scientific, legal and regulatory aspects of this complicated issue," according to materials presented by the Reference Committee on Science & Technology, which recommended the action to the full House.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth